Press Releases.

Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326

Regulus Plans to Re-Initiate Clinical Studies in Q1 2020

Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022

Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches

Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH

No Adverse or Other Significant Findings to Date Across All Dose Groups Tested

Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival

$47 Million Restructured Sanofi Collaboration Executed

Sanofi Will Assume Development of RG-012 for Alport syndrome

Hepatitis B virus Lead Compound Demonstrates Compelling Data in Preclinical Studies

Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway

Efforts Aimed at Extending Cash Runway to mid-2019

Two pre-clinical programs advance towards clinical candidates

Conference Call and Webcast to Follow

Initial safety and pharmacokinetic results from single ascending dose study support advancement

Full enrollment of RG-012 studies anticipated in 2H 2018

Conference Call and Webcast to Follow

Conference Call Today at 5:00 p.m. ET

Conference Call and Webcast to Follow